Clinical Trials Finder
Independent ClinicalTrials.gov directory
ClinicalTrials.gov record
Recruiting Phase 3 Interventional

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

ClinicalTrials.gov ID: NCT05477576

Public ClinicalTrials.gov record NCT05477576. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced May 19, 2026, 8:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy

Study identification

NCT ID
NCT05477576
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
RayzeBio, Inc.
Industry
Enrollment
338 participants

Conditions and interventions

Interventions

  • Everolimus Drug
  • Lanreotide Drug
  • Octreotide Drug
  • RYZ101 Drug
  • Sunitinib Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 23, 2022
Primary completion
Nov 30, 2026
Completion
Nov 30, 2030
Last update posted
Mar 29, 2026

2022 – 2030

United States locations

U.S. sites
32
U.S. states
22
U.S. cities
30
Facility City State ZIP Site status
Research Facility Phoenix Arizona 85054 Active, not recruiting
Research Facility Duarte California 91010 Completed
Research Facility Irvine California 92663 Recruiting
Research Facility Los Angeles California 90095 Active, not recruiting
Research Facility Palo Alto California 94305 Active, not recruiting
Research Facility San Francisco California 94143 Active, not recruiting
Research Facility New Haven Connecticut 06510 Active, not recruiting
Research Facility Washington D.C. District of Columbia 20010 Active, not recruiting
Research Facility Jacksonville Florida 32224 Active, not recruiting
Research Facility Miami Florida 33165 Recruiting
Research Facility Tampa Florida 33607 Recruiting
Research Facility Atlanta Georgia 30322 Active, not recruiting
Research Facility Iowa City Iowa 52242 Recruiting
Research Facility Lexington Kentucky 40536 Recruiting
Research Facility Glen Burnie Maryland 21061 Recruiting
Research Facility Boston Massachusetts 02118 Active, not recruiting
Research Facility Boston Massachusetts 02215 Active, not recruiting
Research Facility Troy Michigan 48098 Completed
Research Facility Rochester Minnesota 55905 Active, not recruiting
Research Facility St Louis Missouri 63110 Recruiting
Research Facility Omaha Nebraska 68130 Recruiting
Research Facility New York New York 10029 Active, not recruiting
Research Facility New York New York 10065 Recruiting
Research Facility Cleveland Ohio 44106 Active, not recruiting
Research Facility Columbus Ohio 43221 Recruiting
Research Facility Portland Oregon 97239 Active, not recruiting
Research Facility Philadelphia Pennsylvania 19104 Active, not recruiting
Research Facility Pittsburgh Pennsylvania 15232 Recruiting
Research Facility Nashville Tennessee 37232 Active, not recruiting
Research Facility Houston Texas 77030 Active, not recruiting
Research Facility Salt Lake City Utah 84112 Recruiting
Research Facility Seattle Washington 98109 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05477576, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 29, 2026 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05477576 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →